Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: Does variable inhibition of interleukin-6 production limit effectiveness in vivo'

Arthritis and Rheumatism

Volumn 62, Issue 11, 2010, Pages 3221-3231

  Page, Theresa H ^a   Brown, Anthony ^a   Timms, Emma M ^a   Foxwell, Brian M J ^c   Ray, Keith P ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DORAMAPIMOD; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SB 731445; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CELL CULTURE; CELL TYPE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM;

ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMIDAZOLES; INTERLEUKIN-6; MACROPHAGES; MONOCYTES; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRAZOLES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE;

EID: 78249269177     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27631     Document Type: Article

References (47)

1. Feldmann M,. Many cytokines are very useful therapeutic targets in disease. J Clin Invest 2008; 118: 3533 - 6.
2. Paleolog E,. The therapeutic potential of TNF-α blockade in rheumatoid arthritis. Expert Opin Investig Drugs 2003; 12: 1087 - 95.
3. Christodoulou C, Choy EH,. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 2006; 6: 13 - 9.
4. Gabay C,. Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2002; 2: 135 - 49.
5. Meyer O,. Role of TNF-α and cytokines in the physiopathology of rheumatoid arthritis: therapeutic perspectives. Bull Acad Natl Med 2003; 187: 935 - 54. In French.
6. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968 - 80.
7. Cuenda A, Rousseau S,. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773: 1358 - 75.
8. Hale KK, Trollinger D, Rihanek M, Manthey CL,. Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages. J Immunol 1999; 162: 4246 - 52.
9. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739 - 46.
10. Kumar S, Boehm J, Lee JC,. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717 - 26.
11. Lee MR, Dominguez C,. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr Med Chem 2005; 12: 2979 - 94.
12. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002; 9: 268 - 72.
13. Saklatvala J,. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004; 4: 372 - 7.
14. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 1997; 4: 311 - 6.
15. Wrobleski ST, Doweyko AM,. Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions. Curr Top Med Chem 2005; 5: 1005 - 16.
16. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297 - 315.
17. Thalhamer T, McGrath MA, Harnett MM,. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008; 47: 409 - 14.
18. Dominguez C, Powers DA, Tamayo N,. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005; 8: 421 - 30.
19. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, DeLora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009; 60: 335 - 44.
20. Ding C,. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs 2006; 7: 1020 - 5.
21. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 325 - 34.
22. Damjanov N, Kauffman RS, Spencer-Green GT,. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009; 60: 1232 - 41.
23. Butler DM, Feldmann M, Di Padova F, Brennan FM,. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts. Eur Cytokine Netw 1994; 5: 441 - 8.
24. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A 2003; 100: 15434 - 9.
25. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127 - 32.
26. Lali FV, Hunt AE, Turner SJ, Foxwell BM,. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 2000; 275: 7395 - 402.
27. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994; 78: 1039 - 49. (Pubitemid 24292331)
28. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M,. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244 - 7.
29. Andreas K, Lubke C, Haupl T, Dehne T, Morawietz L, Ringe J, et al. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther 2008; 10: R9.
30. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 834 - 8.
31. Kinne RW, Stuhlmuller B, Burmester GR,. Cells of the synovium in rheumatoid arthritis: macrophages. Arthritis Res Ther 2007; 9: 224.
32. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A,. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 2005; 280: 19472 - 9.
33. Ono K, Han J,. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1 - 13.
34. Dean JL, Sully G, Clark AR, Saklatvala J,. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004; 16: 1113 - 21.
35. Joshi S, Kaur S, Kroczynska B, Platanias LC,. Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 2010. E-pub ahead of print.
36. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501 - 12.
37. Genovese MC,. Inhibition of p38: has the fat lady sung' [editorial]. Arthritis Rheum 2009; 60: 317 - 20.
38. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, et al. A selective p38α mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 2006; 318: 132 - 41.
39. Mihara K, Almansa C, Smeets RL, Loomans EE, Dulos J, Vink PM, et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFα. Br J Pharmacol 2008; 154: 153 - 64.
40. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H,. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003; 48: 2670 - 81.
41. Rincon M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, et al. Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 1998; 17: 2817 - 29.
42. Ashwell JD,. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 2006; 6: 532 - 40.
43. Jones MR, Quinton LJ, Blahna MT, Neilson JR, Fu S, Ivanov AR, et al. Zcchc11-dependent uridylation of microRNA directs cytokine expression. Nat Cell Biol 2009; 11: 1157 - 63.
44. Palmer CD, Mutch BE, Workman S, McDaid JP, Horwood NJ, Foxwell BM,. Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NF-B activity. Blood 2008; 111: 1781 - 8.
45. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE,. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209 - 20.
46. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M,. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994; 179: 1517 - 27.
47. Gabay C,. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8 Suppl 2: S3.